JP6498439B2 - インフルエンザウイルスワクチン及びその使用 - Google Patents

インフルエンザウイルスワクチン及びその使用 Download PDF

Info

Publication number
JP6498439B2
JP6498439B2 JP2014531931A JP2014531931A JP6498439B2 JP 6498439 B2 JP6498439 B2 JP 6498439B2 JP 2014531931 A JP2014531931 A JP 2014531931A JP 2014531931 A JP2014531931 A JP 2014531931A JP 6498439 B2 JP6498439 B2 JP 6498439B2
Authority
JP
Japan
Prior art keywords
domain
influenza virus
polypeptide
influenza
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014531931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530003A5 (enExample
JP2014530003A (ja
Inventor
ガルシア‐サストレ アドルフォ
ガルシア‐サストレ アドルフォ
パレセ ピーター
パレセ ピーター
クラムメル フロリアン
クラムメル フロリアン
ピカ ナタリー
ピカ ナタリー
エギンク ダーク
エギンク ダーク
エー．メディーナ‐シルバ ラファエル
エー．メディーナ‐シルバ ラファエル
ハイ ロング
ハイ ロング
Original Assignee
アイカーン スクール オブ メディシン アット マウント サイナイ
アイカーン スクール オブ メディシン アット マウント サイナイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカーン スクール オブ メディシン アット マウント サイナイ, アイカーン スクール オブ メディシン アット マウント サイナイ filed Critical アイカーン スクール オブ メディシン アット マウント サイナイ
Publication of JP2014530003A publication Critical patent/JP2014530003A/ja
Publication of JP2014530003A5 publication Critical patent/JP2014530003A5/ja
Application granted granted Critical
Publication of JP6498439B2 publication Critical patent/JP6498439B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2014531931A 2011-09-20 2012-09-19 インフルエンザウイルスワクチン及びその使用 Expired - Fee Related JP6498439B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201161536924P 2011-09-20 2011-09-20
US61/536,924 2011-09-20
US201161565899P 2011-12-01 2011-12-01
US61/565,899 2011-12-01
US201261607526P 2012-03-06 2012-03-06
US61/607,526 2012-03-06
US201261648525P 2012-05-17 2012-05-17
US61/648,525 2012-05-17
US201261670108P 2012-07-10 2012-07-10
US61/670,108 2012-07-10
US201261684481P 2012-08-17 2012-08-17
US61/684,481 2012-08-17
PCT/US2012/056122 WO2013043729A1 (en) 2011-09-20 2012-09-19 Influenza virus vaccines and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018024070A Division JP2018110585A (ja) 2011-09-20 2018-02-14 インフルエンザウイルスワクチン及びその使用

Publications (3)

Publication Number Publication Date
JP2014530003A JP2014530003A (ja) 2014-11-17
JP2014530003A5 JP2014530003A5 (enExample) 2015-11-12
JP6498439B2 true JP6498439B2 (ja) 2019-04-17

Family

ID=47914828

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014531931A Expired - Fee Related JP6498439B2 (ja) 2011-09-20 2012-09-19 インフルエンザウイルスワクチン及びその使用
JP2018024070A Pending JP2018110585A (ja) 2011-09-20 2018-02-14 インフルエンザウイルスワクチン及びその使用
JP2020012913A Pending JP2020096604A (ja) 2011-09-20 2020-01-29 インフルエンザウイルスワクチン及びその使用
JP2022034315A Pending JP2022091775A (ja) 2011-09-20 2022-03-07 インフルエンザウイルスワクチン及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018024070A Pending JP2018110585A (ja) 2011-09-20 2018-02-14 インフルエンザウイルスワクチン及びその使用
JP2020012913A Pending JP2020096604A (ja) 2011-09-20 2020-01-29 インフルエンザウイルスワクチン及びその使用
JP2022034315A Pending JP2022091775A (ja) 2011-09-20 2022-03-07 インフルエンザウイルスワクチン及びその使用

Country Status (17)

Country Link
US (3) US10131695B2 (enExample)
EP (2) EP2758075B1 (enExample)
JP (4) JP6498439B2 (enExample)
KR (1) KR20140068205A (enExample)
CN (3) CN116162175A (enExample)
AR (1) AR090392A1 (enExample)
AU (2) AU2012312529B2 (enExample)
BR (1) BR112014006694A2 (enExample)
CA (1) CA2849434A1 (enExample)
EA (1) EA201490659A1 (enExample)
ES (1) ES2953393T3 (enExample)
HK (1) HK1200102A1 (enExample)
IL (2) IL231547B (enExample)
IN (1) IN2014CN02114A (enExample)
MX (1) MX2014003308A (enExample)
SG (1) SG11201400743VA (enExample)
WO (1) WO2013043729A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
KR20140068205A (ko) 2011-09-20 2014-06-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP6535675B2 (ja) 2013-10-02 2019-06-26 メディミューン，エルエルシー 抗ａ型インフルエンザ抗体の中和及びその使用
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
RU2021109685A (ru) * 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
US20170121373A1 (en) * 2014-05-30 2017-05-04 Sanofi Pasteur Inc. Expression and conformational analysis of engineered influenza hemagglutinin
IL249704B (en) * 2014-07-10 2021-03-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
CN113563462B (zh) 2014-07-15 2024-08-13 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
CN107921097A (zh) * 2015-05-04 2018-04-17 埃皮瓦克斯公司 流感a/shanghai/2/2013 h7序列的改性h7血凝素糖蛋白
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
WO2016205347A1 (en) * 2015-06-16 2016-12-22 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
EP3411712B1 (en) * 2016-02-03 2025-11-19 CG Discovery, Inc. Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
JP6868763B2 (ja) * 2016-04-01 2021-05-12 パナソニックＩｐマネジメント株式会社 インフルエンザウィルスに結合する抗体
US20190125859A1 (en) * 2016-06-03 2019-05-02 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3464327A1 (en) * 2016-06-03 2019-04-10 Sanofi Pasteur Inc. Modification of engineered influenza hemagglutinin polypeptides
WO2017218624A1 (en) * 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
JP7183149B2 (ja) 2016-09-02 2022-12-05 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用
WO2018085488A1 (en) 2016-11-02 2018-05-11 Iowa State University Research Foundation, Inc. Universal mammalian influenza vaccine
US20180128545A1 (en) * 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018175560A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JP2021519596A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ フェリチンタンパク質
KR20210018206A (ko) * 2018-04-03 2021-02-17 사노피 항원성 호흡기 세포융합 바이러스 폴리펩타이드
US12304928B2 (en) 2018-05-18 2025-05-20 Cz Biohub Sf, Llc Epitope restriction for antibody selection
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US20210225457A1 (en) * 2018-07-13 2021-07-22 University Of Georgia Research Foundation Methods for generating pan-epitopic immunogens of influenza h3 virus, compositions and methods of use thereof
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN109096376A (zh) * 2018-09-20 2018-12-28 扬州大学 流感病毒ha多肽、klh偶联多肽及多克隆抗体的制备方法
KR102098585B1 (ko) * 2018-11-21 2020-04-08 고려대학교 산학협력단 교차 면역원성을 갖는 h2 아형 인플루엔자 바이러스 및 이를 포함하는 백신
JP7621270B2 (ja) 2019-04-05 2025-01-24 アカデミア シニカ シアリダーゼ耐性糖およびその調製および使用方法
CA3132697A1 (en) * 2019-04-06 2020-10-15 Scot ROBERTS Broad and long-lasting influenza vaccine
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
WO2021055679A1 (en) * 2019-09-20 2021-03-25 Academia Sinica Chimeric hemagglutinin protein and a vaccine composition comprising the same
EP4045517A2 (en) * 2019-10-15 2022-08-24 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
WO2021226533A1 (en) 2020-05-08 2021-11-11 Academia Sinica Chimeric influenza vaccines
CN112111503B (zh) * 2020-08-24 2023-04-07 河北省动物疫病预防控制中心 同时预防禽流感h5和h9亚型的腺病毒载体二价苗及其制备方法
US20240050551A1 (en) * 2021-01-12 2024-02-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Herpes simplex virus type 1 derived influenza vaccine
CN113082187B (zh) * 2021-04-09 2023-06-27 北京红太阳药业有限公司 小柴胡提取物与阿奇霉素联合在治疗病毒性肺炎中的应用
IL318755A (en) 2021-04-12 2025-04-01 Academia Sinica Improved vaccine for the coronavirus
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
KR102923529B1 (ko) * 2022-12-14 2026-02-05 중앙대학교 산학협력단 인플루엔자 a형 바이러스 검출용 신규한 펩타이드
WO2024215614A2 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
WO2024215612A2 (en) 2023-04-08 2024-10-17 Roc Biomedical Inc. Methods and compositions for targeted delivery by polymersomes
KR20260013456A (ko) 2023-05-17 2026-01-28 락 바이오메디컬 인크. Mgat1 결핍 세포 및 이의 용도
WO2025092866A1 (zh) * 2023-10-31 2025-05-08 仁景(苏州)生物科技有限公司 一种多价流感mRNA疫苗

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
US5182192A (en) 1987-03-27 1993-01-26 The Wistar Institute Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
JP3037554B2 (ja) 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
EP0621339B1 (en) 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
WO1994016109A1 (en) 1993-01-15 1994-07-21 Whitehead Institute For Biomedical Research Membrane fusion events and means for altering same
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5573916A (en) 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
EP1394259A3 (en) 1994-07-18 2004-04-14 Karl-Klaus Prof. Dr. Conzelmann Recombinant infectious non-segmented negative strand RNA virus
EP0789774A2 (en) 1994-10-03 1997-08-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
ES2326705T3 (es) 1995-09-14 2009-10-16 Virginia Tech Intellectual Properties, Inc. Produccion de enzimas lisosomicas en sistemas de expresion basados en plantas.
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
AU722327B2 (en) 1996-04-19 2000-07-27 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
US6942861B2 (en) 1996-04-19 2005-09-13 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
ATE451451T1 (de) 1996-07-15 2009-12-15 Us Gov Health & Human Serv Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
KR20000048628A (ko) 1996-09-27 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 모노네가비랄레스 목의 바이러스에서 감쇠를 책임지는 3' 게놈프로모터 영역 및 폴리머라제 유전자 돌연변이
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN1250725C (zh) 1997-05-23 2006-04-12 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒副流感病毒疫苗的方法
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
JP4434478B2 (ja) 1997-07-11 2010-03-17 イエール ユニバーシティー リエンジニアリングされた外被を有するラブドウイルス
WO1999015672A1 (en) 1997-09-19 1999-04-01 American Cyanamid Company Attenuated respiratory syncytial viruses
EP1098961B1 (en) 1998-06-12 2008-01-16 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
DK2316923T3 (en) 1998-06-12 2018-01-08 Icahn School Med Mount Sinai Attenuated influenza viruses with altered interferon antagonist activity for use as vaccines and drugs
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
AU776855B2 (en) 1998-12-23 2004-09-23 Boyce Thompson Institute For Plant Research Inc. Expression of immunogenic hepatitis B surface antigens in transgenic plants
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
AU4134000A (en) 1999-04-29 2000-11-17 Syngenta Limited Herbicide resistant plants
EP1194580B2 (en) 1999-07-14 2010-08-25 Mount Sinai School of Medicine of New York University In vitro reconstitution of segmented negative-strand rna viruses
AR025750A1 (es) 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
CN100489107C (zh) 2000-04-28 2009-05-20 圣朱德儿童研究医院 用于产生感染性流感病毒的dna转染系统
US6632620B1 (en) 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
BRPI0111830B8 (pt) * 2000-06-23 2021-05-25 American Cyanamid Co método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas
EP3009507B1 (en) 2002-02-13 2020-06-24 Wisconsin Alumini Research Foundation Signal for packaging of influenza virus vectors
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
BR0313650A (pt) * 2002-08-20 2007-08-14 Genitrix Llc composição, vetor de expressão, composição de vacina e uso
WO2004067553A2 (en) 2003-01-29 2004-08-12 The Research Foundation Of The State University Of New York Tolerance-induced targeted antibody production
JP4675317B2 (ja) 2003-01-30 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化インフルエンザワクチン
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4368594B2 (ja) 2003-02-24 2009-11-18 株式会社インシリコサイエンス タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
CN100393870C (zh) 2003-05-05 2008-06-11 波依斯汤普森植物研究所 用于制备免疫保护性组合物的载体和来源于转基因植物的细胞
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8551756B2 (en) 2003-07-11 2013-10-08 Novavax, Inc. Avian influenza chimeric VLPS
DK2261376T3 (da) 2003-11-04 2013-10-07 Univ Tulane Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner
EP1766059B1 (en) 2004-05-25 2012-07-11 MedImmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
JP2008515454A (ja) 2004-10-13 2008-05-15 プロタリクス リミテッド 植物細胞培養における抗体製造のシステムおよび方法
EP2923711A1 (en) * 2004-11-03 2015-09-30 Novartis Vaccines and Diagnostics, Inc. Influenza vaccination
CA2598884A1 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
EP1885186B1 (en) 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
JP4758148B2 (ja) 2005-06-14 2011-08-24 泰三 宇田 インフルエンザウイルスのヘマグルチニンに対する抗体酵素
KR20070000554A (ko) 2005-06-27 2007-01-03 삼성전자주식회사 이종 망에서 복합 서비스를 위한 자원 관리방법
PE20070171A1 (es) 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
PL1951299T3 (pl) 2005-11-04 2012-07-31 Novartis Ag Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność
EP2251034B1 (en) 2005-12-02 2018-02-14 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
ES2385842T3 (es) 2005-12-06 2012-08-01 Yeda Research And Development Co., Ltd. Vacuna mejorada contra la gripe
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
JP2009526526A (ja) 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド インフルエンザ抗原、ワクチン組成物、および関連する方法
US20070207171A1 (en) 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
EP3011969A1 (en) 2006-03-07 2016-04-27 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
WO2007130330A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
US20070262178A1 (en) 2006-05-12 2007-11-15 Ultradent Products, Inc. Syringe delivery tip including an enlarged flocked wing element adjacent a distal delivery end
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
WO2007134327A2 (en) 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
WO2008054540A2 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2008002238A1 (en) 2006-06-27 2008-01-03 Addbio Ab Drug delivery device , kit and method for peroperative local pharmacological treatment of bone surfaces
WO2008005777A2 (en) 2006-06-30 2008-01-10 Novavax, Inc. Methods of enhancing protein incorporation into virus like particles
AU2007275010B2 (en) 2006-07-21 2013-06-20 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008032219A2 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
CN101607995B (zh) 2007-06-15 2013-05-01 厦门大学 特异性结合h5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途
EP2014279A1 (en) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
HRP20120790T1 (hr) 2007-06-27 2013-01-31 Novartis Ag Cjepiva protiv influence sa niskom koliäśinom aditiva
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
DK2540312T3 (en) 2007-07-19 2015-07-20 Novavax Inc Chimeric avian influenza VLPs
US20090092635A1 (en) 2007-08-17 2009-04-09 Wyeth Heterologous prime-boost immunization regimen
EP2200639B1 (en) 2007-09-24 2016-03-30 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use
FR2921387B1 (fr) 2007-09-26 2012-04-20 Sanofi Pasteur Procede de production du virus de la grippe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
PT2610345E (pt) 2007-11-27 2016-01-11 Medicago Inc Partículas semelhantes ao vírus (vlps) da gripe recombinantes produzidas em plantas transgénicas que expressam hemaglutinina
MX2010006148A (es) 2007-12-06 2011-02-23 Dana Farber Cancer Inst Inc Anti-cuerpos contra el virus de la influenza y metodos de uso de los mismos.
WO2009092038A1 (en) 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
ES2524553T3 (es) 2008-06-17 2014-12-10 Apogenix Gmbh Receptores multiméricos de TNF
EA019138B1 (ru) 2008-06-25 2014-01-30 Инсэрм (Инститют Насиональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Новые иммуноадъювантные соединения на основе флагеллина и их применение
EP2294202B1 (en) * 2008-07-08 2015-05-20 Medicago Inc. Soluble recombinant influenza antigens
WO2010036948A2 (en) 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
CA2787099A1 (en) * 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
WO2010130636A1 (en) 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
JP5871796B2 (ja) 2009-06-24 2016-03-01 メディカゴ インコーポレイテッド ヘマグルチニンを含むキメラインフルエンザウイルス様粒子
CA2805505C (en) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
JP5463107B2 (ja) * 2009-09-14 2014-04-09 独立行政法人国立国際医療研究センター 新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬
WO2011044152A1 (en) 2009-10-05 2011-04-14 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer Protection against pandemic and seasonal strains of influenza
JP2013060367A (ja) * 2010-01-15 2013-04-04 Osaka Univ 抗インフルエンザ抗体及びインフルエンザ検出用デバイス
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
US9573991B2 (en) 2010-03-08 2017-02-21 Celltrion, Inc. Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
EP2596017B1 (en) 2010-07-22 2019-04-03 John W. Schrader Cross-protective antibody against influenza viral infection
KR20140068205A (ko) 2011-09-20 2014-06-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
MY170927A (en) 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
CA2894506C (en) 2012-12-11 2021-08-10 Vib Vzw Anti-influenza antibody
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
CN109045294A (zh) 2013-01-10 2018-12-21 思齐乐 流感病毒免疫原性组合物及其应用
HK1218511A1 (zh) 2013-03-13 2017-02-24 Novartis Ag 乙型流感病毒重配
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN105209071A (zh) 2013-03-14 2015-12-30 抗非特公司 用于提高疗效的基于鼻内递送中和抗体的组合物和方法
HK1216723A1 (zh) 2013-03-15 2016-12-02 The Trustees Of The University Of Pennsylvania 流感核酸分子和由其製備的疫苗
PL235555B1 (pl) 2014-06-24 2020-09-07 Inst Biotechnologii I Antybiotykow Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
WO2016205347A1 (en) 2015-06-16 2016-12-22 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US20190125859A1 (en) 2016-06-03 2019-05-02 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof

Also Published As

Publication number Publication date
AU2018202388A1 (en) 2018-04-26
US20260001918A1 (en) 2026-01-01
JP2018110585A (ja) 2018-07-19
HK1200102A1 (en) 2015-07-31
CN108164602A (zh) 2018-06-15
BR112014006694A2 (pt) 2020-11-17
CA2849434A1 (en) 2013-03-28
JP2014530003A (ja) 2014-11-17
CN116162175A (zh) 2023-05-26
EP4241785A3 (en) 2023-09-27
US20150132330A1 (en) 2015-05-14
EP2758075A1 (en) 2014-07-30
CN104185476A (zh) 2014-12-03
IL231547B (en) 2018-10-31
AU2012312529A1 (en) 2014-03-27
IL231547A0 (en) 2014-04-30
IL262123A (en) 2018-11-29
US10131695B2 (en) 2018-11-20
EP2758075B1 (en) 2023-05-03
SG11201400743VA (en) 2014-04-28
EP2758075A4 (en) 2015-05-20
IN2014CN02114A (enExample) 2015-05-29
US20190106461A1 (en) 2019-04-11
EA201490659A1 (ru) 2014-11-28
WO2013043729A1 (en) 2013-03-28
JP2022091775A (ja) 2022-06-21
AR090392A1 (es) 2014-11-12
AU2012312529B2 (en) 2018-01-04
EP4241785B1 (en) 2026-01-28
MX2014003308A (es) 2015-03-09
EP4241785A2 (en) 2023-09-13
JP2020096604A (ja) 2020-06-25
KR20140068205A (ko) 2014-06-05
ES2953393T3 (es) 2023-11-10

Similar Documents

Publication Publication Date Title
JP6498439B2 (ja) インフルエンザウイルスワクチン及びその使用
US20260048114A1 (en) Influenza virus vaccination regimens
US10179806B2 (en) Influenza virus vaccines and uses thereof
US9849172B2 (en) Influenza virus vaccines and uses thereof
JP2023088962A (ja) インフルエンザウイルスワクチン及びその使用
HK1216392B (en) Influenza virus vaccines and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190131

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190313

R150 Certificate of patent or registration of utility model

Ref document number: 6498439

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees